EP Patent

EP1578438B1 — Synthetic peptide analogs for the treatment of cancer

Assigned to Dabur Research Foundation · Expires 2007-06-06 · 19y expired

What this patent protects

The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell p…

USPTO Abstract

The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.

Drugs covered by this patent

Patent Metadata

Patent number
EP1578438B1
Jurisdiction
EP
Classification
—
Expires
2007-06-06
Drug substance claim
No
Drug product claim
No
Assignee
Dabur Research Foundation
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.